News & Trends - Pharmaceuticals

Arrotex boosts respiratory portfolio to $263m with new Boehringer Ingelheim partnership

Health Industry Hub | February 6, 2020 |
[Total: 1    Average: 4/5]

Arrotex Pharmaceuticals is today announcing a strategic partnership with Boehringer Ingelheim for the exclusive Australian reseller rights to respiratory brand Spiriva.

Used for the treatment of chronic obstructive pulmonary disease (COPD), the Spiriva brand currently has a market value of AUD 34 million, increasing Arrotex’ respiratory portfolio to AUD 263.5 million.

Following the 2019 merger of Apotex and Arrow Pharmaceuticals, the combined Arrotex entity now promotes GSK’s Seretide, Pavtide (Seretide authorised generic), Flixotide and Ventolin brands along with AstraZeneca’s respiratory brands Symbicort, Pulmicort, Omnaris, Alvesco, Bricanyl and Oxis.

Arrotex told Health Industry Hub that GSK, AstraZeneca and Boehringer Ingelheim will continue to promote these brands to GPs via their internal field forces. Arrotex’s extensive pharmacy sales team will promote the respiratory products to all community pharmacies.

Enhance corporate branding and boost thought leadership to attract and retain quality employees. Health Industry Hub is the only one-stop-hub connecting Australia’s Pharma, MedTech, and Biotech industry professionals. Get started with our proven digital media solutions developed by industry for industry.

Lisa Golden, Arrotex Chief Commercial Officer said: “Strategic partnerships such as this new Boehringer Ingelheim arrangement, as well as existing collaborations with GSK and AstraZeneca, represent a unique element of the Apotex and Arrow offer to pharmacy.

“Through our strategic partnerships, Arrotex creates value for Australian community pharmacy, by offering access to brand product discounts that would otherwise be unavailable to our customers. This is an example of Arrotex’ unique approach to value creation for our customers who are operating in the competitive retail pharmacy market,” she said.

The partnership with Boehringer Ingelheim will take effect 10 February 2020 and Apotex and Arrow will soon contact pharmacies with details of commercial arrangements.

Register FREE to receive the latest news, innovations and insights from Health Industry Hub; the only one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals and its key stakeholders.

You may also like Novartis’ new drug – an attractive option in AMD treatment


About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

News & Trends - Pharmaceuticals

First immunotherapy PBS listed in small cell lung cancer - Pharma News

First immunotherapy treatment PBS listed in small cell lung cancer

Health Industry Hub | February 19, 2020 |

Pharma News: Effective 1 March 2020 the first immunotherapy treatment for small cell lung cancer (SCLC) will be available on […]

More


News & Trends - Medical Technology

Blood test to improve ovarian cancer diagnosis - MedTech News

Blood test to improve ovarian cancer diagnosis

Health Industry Hub | February 19, 2020 |

MedTech News: Australian researchers have developed a simple blood test that measures the body’s own immune response to improve diagnosis […]

More


Medical

The largest healthcare event in the region - Australian Healthcare Week - Medical News

Don’t miss the largest healthcare event in the region – Australian Healthcare Week

Health Industry Hub | February 19, 2020 |

Health Industry Hub is proud to partner with and support the free-to-attend 10th Annual Australian Healthcare Week Expo, held March […]

More


News & Trends - Pharmaceuticals

BMS announces new 5-year data in advanced renal cell carcinoma - Pharma News

BMS announces new 5-year data in advanced renal cell carcinoma

Health Industry Hub | February 19, 2020 |

Pharma News: Bristol-Myers Squibb announced five-year follow-up study results demonstrating that Opdivo (nivolumab) treatment delivers superior overall survival (OS) and […]

More